Sat.Nov 25, 2023

article thumbnail

Revolutionizing patient care: the convergence of AI and personalized medicine

KevinMD

In the dynamic realm of health care, two revolutionary forces are converging to redefine patient care: artificial intelligence (AI) and personalized medicine. This synergy transforms how we understand, diagnose, and treat diseases, tailoring health care to each patient’s needs. The emergence of personalized medicine Personalized medicine, at its core, is about understanding the unique genetic, Read more… Revolutionizing patient care: the convergence of AI and personalized medicine original

Health IT 467
article thumbnail

Weekly Roundup – November 25, 2023

Healthcare IT Today

Welcome to our Healthcare IT Today Weekly Roundup. Each week, we’ll be providing a look back at the articles we posted and why they’re important to the healthcare IT community. We hope this gives you a chance to catch up on anything you may have missed during the week. Looking at the Latest in Real-Time Clinical Note Generation. John Lynn spoke to Dr.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

'Roll-Up Strategies to create Platforms' likely to define the HealthTech landscape in 2024

Lloyd Price

Exec Summary: Rollup strategies are expected to play a significant role in shaping the HealthTech landscape in 2024. This approach involves acquiring multiple smaller companies within a specific sector and consolidating them into a larger, more unified entity. This strategy offers several potential benefits, including: Increased Scale and Efficiency: By combining resources and expertise, rollups can achieve greater economies of scale, leading to improved operational efficiency and reduced costs.

article thumbnail

Average Multiples and Key Drivers of Digital Therapeutics (DTx) M&A deals in 2023

Lloyd Price

Executive Summary: The average multiples for digital therapeutics (DTx) M&A deals in 2023 are as follows: Enterprise value (EV) to sales: 5.6x EV to EBITDA: 12.5x These multiples are down from the levels seen in 2022, but they are still higher than the average EV to sales multiple for all industries. The decline in multiples is likely due to a number of factors, including: The increasing number of DTx companies entering the market The increasing competition from traditional pharmaceutical co

article thumbnail

Less Stress, More Success: Accounting Best Practices & Processes for 2025

Speaker: Amanda Adams, Fractional CFO, CPA

Are you ready to elevate your accounting processes for 2025? 🚀 Join us for an exclusive webinar led by Amanda Adams, a seasoned fractional CFO and CPA passionate about transforming back-office operations for finance teams. This session will cover critical best practices and process improvements tailored specifically for accounting professionals.